Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Urowitz, Murray B
Gladman, Dafna D
Wallace, Daniel J
Clarke, Ann E
Ginzler, Ellen M
Isenberg, David A
Merrill, Joan T
Alarcón, Graciela S
Fessler, Barri J
Fortin, Paul R
Hanly, John G
Dooley, Mary Anne
Khamashta, Munther A
Zoma, Asad A
Sturfelt, Gunnar K
van Vollenhoven, Ronald F
Kalunian, Kenneth C
Lim, S Sam
Kamen, Diane L
Peschken, Christine A
Bruce, Ian N
MetadataShow full item record
CitationAnn. Rheum. Dis. 2015, 74 (8):1530-6
AbstractThe metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.
Recently diagnosed (<15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression.
We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index >1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort.
MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to Annals of the rheumatic diseases
- Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
- Authors: Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN
- Issue date: 2013 Aug
- Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age.
- Authors: Medeiros MM, Xavier de Oliveira ÍM, Ribeiro ÁT
- Issue date: 2016 Jan
- Prevalence and features of metabolic syndrome in childhood-onset systemic lupus erythematosus.
- Authors: Sinicato NA, Postal M, de Oliveira Peliçari K, Rittner L, Marini R, Appenzeller S
- Issue date: 2017 Jul
- Metabolic syndrome in patients with systemic lupus erythematosus: Association with disease activity, disease damage and age.
- Authors: Mobini M, Niksolat F, Mohammadpour RA, Dashti Dargahloo S, Marzban D
- Issue date: 2018 May
- Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants.
- Authors: Fatemi A, Ghanbarian A, Sayedbonakdar Z, Kazemi M, Smiley A
- Issue date: 2018 Jun